UNSPSC 51262605: Atipamezole hydrochloride

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C14H16N2.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2W4279571X. The term atipamezole hydrochloride is a U.S. FDA Green Book designation. Most nations, for tariff and trade purposes, schedule atipamezole hydrochloride under HS 29332990 and SITC 51573. As of Q4 2014, ATIPAMEZOLE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Atipamezole hydrochloride bears US NLM identifiers UMLS ID C1289965 and NCI Concept Code C80011.

SMILES: CCC1(CC2CCCCC2C1)C3CNC[NH]3.CL.

UNSPSC 51262605 Atipamezole hydrochloride is a Commodity code that state and local governments appear to procure as part of broader pharmaceutical and clinical supply acquisitions, though recent solicitations tagged to this code show limited direct activity under the atipamezole specification alone. The code sits within pharmaceutical and medical supply procurement, where state and local health departments, county health systems, and state health and human services agencies acquire medications, emergency medical supplies, and pharmacy benefit management services. Issuing bodies in the recent record include county health departments (Seminole County, Florida) and state-level health and human services commissions (Texas Health and Human Services Commission), suggesting the code serves regional and statewide health infrastructure rather than school districts or transit authorities.

The most recent activity is geographically concentrated in Florida and Texas. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with a response deadline of July 26, 2023 (note: date inconsistency in source). The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, soliciting vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to gather market intelligence on direct contracting between state pharmacy benefit programs and manufacturers. Both solicitations indicate state and local interest in pharmacy supply chain efficiency and cost management, though the Seminole County opportunity focuses on emergency medical supplies and the Texas RFI targets manufacturer relationships rather than atipamezole specifically.